India’s obesity burden is rising fast. Emcure Pharmaceuticals is stepping in with a new treatment option. The company has announced the commercial launch of Poviztra (semaglutide injection) across India, expanding access to evidence-backed weight management therapy.
What Is Poviztra?
Poviztra is a once-weekly semaglutide injection designed for chronic weight management.
Key highlights:
- Second brand of Novo Nordisk’s semaglutide for weight management
- Exclusively distributed and commercialised by Emcure in India
- Delivered via a prefilled, easy-to-use pen device
Available Strengths and Pricing
Poviztra is available in five dosing strengths:
- 0.25 mg
- 0.5 mg
- 1.0 mg
- 1.7 mg
- 2.4 mg (maintenance dose)
Pricing starts at ₹8,790 per month, covering four weekly doses.
The pen device allows precise dosing with minimal administration complexity, improving patient adherence.
Clinical Evidence Behind Semaglutide
Semaglutide is not new to the global market.
Its credentials include:
- Backed by the STEP and SELECT clinical trial programmes
- Nearly 10 years of global market presence
- Over 38 million patient-years of exposure
- Strong safety and efficacy profile supported by real-world data
In clinical trials, many patients achieved over 20% weight loss.
Approved Indications
Poviztra is indicated for adults as an adjunct to diet and exercise in:
- Obesity (BMI ≥30 kg/m²)
- Overweight (BMI ≥27 kg/m²) with at least one comorbidity, such as:
- Type 2 diabetes
- Hypertension
- Dyslipidaemia
It is also approved to:
- Reduce the risk of major adverse cardiovascular events
- Applicable for patients with cardiovascular disease and obesity or overweight
Why This Launch Matters?
India faces a serious obesity challenge:
- ~254 million people with generalised obesity
- ~351 million with abdominal obesity
Obesity is linked to 230+ health complications, including cardiovascular disease, fatty liver, osteoarthritis, PCOS, kidney disease, and Alzheimer’s.
According to Emcure’s leadership, Poviztra aims to close the gap between clinical innovation and real-world access.
Emcure’s Strategic Play
With Poviztra, Emcure is leveraging:
- Its pan-India distribution network
- Strong experience in commercialising complex therapies
- A growing focus on chronic and lifestyle-related diseases
The launch reinforces Emcure’s push toward patient-centric, science-led therapies in high-burden disease areas.
The Bigger Picture
Weight management is shifting from lifestyle advice to clinically validated pharmacotherapy. With Poviztra, Emcure positions itself early in India’s fast-evolving obesity treatment market. For patients, it means more choice, broader access, and evidence-backed care.
